title: Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG)
abstract: In a phase II study, patients with refractory myelomatosis were treated with a combination chemotherapy (NOP regimen): mitoxantrone (bolus injection of 4 mg/m2 on days 1-4), vincristine (continuous infusion of 0.4 mg/24 h on days 1-4) and prednisone (250 mg/d on days 1-4 and 17-20). The treatment was repeated every 4 weeks. Ninety-two patients were treated after they were found refractory to treatment with melphalan and prednisone (and occasionally vincristine) (n = 50) or more intensive treatment regimens (n = 42) including anthracyclines (n = 18). Response (greater than or equal to 50% reduction of M protein) was obtained in 23 patients and minor response (clinical improvement but less than 50% reduction in M protein) in 22 patients. The median duration of the response was 7.5 months. Equal response rates were observed irrespective of the type of previous treatment. The major toxicity was myelosuppression with severe granulocytopenia and infections. However, the frequency decreased throughout the cycles. The NOP treatment is recommended in refractory myelomatosis, especially in patients refractory to other intensive regimens. Patients in a poor clinical condition or with thrombocytopenia before treatment should have a reduced mitoxantrone dose in the first treatment cycles.
authors.affiliation: Department of Internal Medicine and Haematology L, University Hospital, Copenhagen, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Gimsing
authors.forename: O W
authors.initials: OW
authors.lastname: Bjerrum
authors.forename: E
authors.initials: E
authors.lastname: Brandt
authors.forename: J
authors.initials: J
authors.lastname: Ellegaard
authors.forename: S A
authors.initials: SA
authors.lastname: Evensen
authors.forename: M M
authors.initials: MM
authors.lastname: Hansen
authors.forename: M
authors.initials: M
authors.lastname: Hedenus
authors.forename: E
authors.initials: E
authors.lastname: Hippe
authors.forename: N
authors.initials: N
authors.lastname: Keldsen
authors.forename: I
authors.initials: I
authors.lastname: Palva
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D008942:Mitoxantrone; D011241:Prednisone